stoxline Quote Chart Rank Option Currency Glossary
Kintara Therapeutics, Inc. (KTRA)
0.2471  -0.028 (-10.11%)    06-21 16:00
Open: 0.3085
High: 0.3368
Volume: 36,970,992
Pre. Close: 0.2749
Low: 0.24
Market Cap: 14(M)
Technical analysis
2024-06-21 4:53:33 PM
Short term     
Mid term     
Targets 6-month :  0.35 1-year :  0.48
Resists First :  0.3 Second :  0.41
Pivot price 0.22
Supports First :  0.12 Second :  0.1
MAs MA(5) :  0.22 MA(20) :  0.22
MA(100) :  0.14 MA(250) :  1.57
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  33.4 D(3) :  22.1
RSI RSI(14): 57.2
52-week High :  5.59 Low :  0.08
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ KTRA ] has closed below upper band by 36.1%. Bollinger Bands are 97.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 16 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.34 - 0.34 0.34 - 0.34
Low: 0.24 - 0.24 0.24 - 0.24
Close: 0.24 - 0.25 0.25 - 0.25
Company Description

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

Headline News

Mon, 03 Jun 2024
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel ... - PR Newswire

Tue, 14 May 2024
Kintara Therapeutics Reports Improved Q3 Results - - TipRanks

Tue, 14 May 2024
Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results - PR Newswire

Thu, 04 Apr 2024
Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA - Yahoo Finance

Wed, 03 Apr 2024
Kintara Merges with TuHURA to Advance Cancer Therapy - - TipRanks

Wed, 03 Apr 2024
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 55 (M)
Shares Float 55 (M)
Held by Insiders 0.1 (%)
Held by Institutions 0.8 (%)
Shares Short 1,130 (K)
Shares Short P.Month 700 (K)
Stock Financials
EPS -2.32
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.08
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -83 %
Return on Equity (ttm) -192.3 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.17
Qtrly Earnings Growth 0 %
Operating Cash Flow -7 (M)
Levered Free Cash Flow -5 (M)
Stock Valuations
PE Ratio -0.11
PEG Ratio 0
Price to Book value -3.09
Price to Sales 0
Price to Cash Flow -1.89
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android